2025年半年报点评:对外许可常态化,员工持股计划明确创新药产出规划

东方财富
Sep 09

恒瑞医药(600276)事件公司发布2025年半年报,上半年实现营业收入157.6亿元(+15.9%)、归母净利润44.5亿元(+29.7%)、扣非归母净利润42.7亿元(+22.4%);25Q2实现营业收入85.6亿元(+12.5%)、归母净利润25.8亿元(+24.9%)、扣非归母净利润24.1亿元(+17.6%)。核心观点25H1许可收入19.9亿元,创新药稳健增长25H1拆分来看,销售商品...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10